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Abstract: The treatment of glioblastoma remains a major challenge for clinicians since these highly
aggressive brain tumors are relatively resistant towards radio- and chemotherapy. The pathways that
control apoptosis are altered in glioblastoma cells leading to resistance towards apoptotic stimuli in
general. In this review we describe the alterations affecting the p53 pathway, the BCL-2 protein family,
the inhibitor of apoptosis proteins and several growth factor pathways involved in the regulation of
programmed cell death and define possible targets for new therapies within these apoptotic pathways in
glioblastomas. Moreover, we review strategies to target death receptor pathways, most notably to render
the glioblastoma cells more susceptible towards this approach without enhancing toxicity in general.
Most of the strategies targeting apoptosis in glioblastomas presented here are in a pre-clinical stage
of development, however, they all share the ultimative goal to improve the outcome for glioblastoma
patients.
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RESPONSE 
 
Whole-brain radiotherapy for primary CNS lymphoma? 
 
The G-PCNSL-SG-1 trial is the only completed randomized phase III trial in patients with 
primary CNS lymphoma (PCNSL) (1). It answered the question repeatedly identified in many 
review articles as the most challenging and important question to answer in the treatment of 
PCNSL: does the omission of whole brain radiotherapy (WBRT) from the treatment of newly 
diagnosed PCNSL compromise survival? The answer is no.  
G-PCNSL-SG-1 was an investigator-initiated trial that was done without industry funding and 
designed in 1998. It should not be judged by quality criteria of present industry-sponsored 
trials. We detailed limitations in our Article and find no new considerations in the comments 
of Ferreri and colleagues. 
(i) Although our eligibility criteria were much the same as in many smaller trials, we enrolled 
a patient population with a high median age (63 years [nearly a quarter over 70 years]) and 
low Karnofsky performance scores. We showed a complete-response rate of 32.4% in 401 
patients which compares favourably with 18% in 40 patients in a contemporary oligocentric 
trial by the International Extranodal Lymphoma Study Group (2).  
(ii) By contrast to the latter study (2), we analysed a possible negative impact on outcome 
from centers with a small patient volume, but did not identify one, suggesting that 
decentralised care is not harmful to outcome. 
(iii) We did not monitor neurotoxicity only by MRI, but also clinically, which does not differ 
from the technique used by many other investigators.. 
(iv) The statement that 40% of the patients were excluded from analysis is misleading, if not 
deliberately unfair. Randomisation was appropriately done up-front, before high-dose 
methotrexate-based chemotherapy, but could only become effective if patients were eligible 
for either consolidation or salvage. Patients would thus inevitably be lost during the intended 
six cycles of chemotherapy. Moreover, the second, not unexpected loss of patients occurred 
(a) at the step where randomisation led patients in complete remission to receive WBRT and 
(b) patients without complete remission to receive second-line chemotherapy instead of 
WBRT. Such a randomisation is difficult to perform, but is the only way to address the value 
of WBRT. We assume that later randomization after completion of chemotherapy would have 
made randomization even more difficult. Yet, when all patients included (n=551) and all 
patients meeting eligibility criteria who were started on primary chemotherapy (n=526) were 
analysed for outcome, similar results for the primary endpoint as in the PP and ITT 
populations were found, indicating that the study results were not biased by patient selection. 
Of 411 ITT patients at the beginning of the randomised intervention, 318 (77%) were 
included in the PP analysis. 
(v) We would like to thank our colleagues for pointing out one of our major findings: WBRT 
can be postponed until relapse without compromising survival. Yet, it is trivial that options 
for treatment at first recurrence differed between study arms in our trial: patients who 
received chemotherapy alone as their first-line therapy often had WBRT later on whereas 
already irradiated patients did not receive a second course of WBRT. The salvage 
chemotherapy protocols were similar in both arms.  
In conclusion, G-PCNSL-SG-1 proves that randomized phase III trials with an adequate 
number of patients are possible in this rare disease. It has set a standard of clinical trial design 
and conduct in PCNSL. Ferreri and colleagues define this standard as low here. We encourage 
them to join forces and show as early as possible that improved trials with more definitive 
answers can be undertaken. Time will tell. 
 
Agnieszka Korfel, Peter Martus, Eckhard Thiel, Berlin, Germany 
Michael Weller, Zurich, Switzerland, 
For the German PCNSL Study Group 
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